Relationship between Advanced Glycation End Products and Plaque Progression in Patients with Acute Coronary Syndrome: The JAPAN-ACS Sub-study

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Fukushima, Yoshifumi ^a   Daida, Hiroyuki ^a   Morimoto, Takeshi ^b   Kasai, Takatoshi ^a   Miyauchi, Katsumi ^a   Yamagishi, Sho ichi ^c   Takeuchi, Masayoshi ^d   Hiro, Takafumi ^e   Kimura, Takeshi ^f   Nakagawa, Yoshihisa ^g   Yamagishi, Masakazu ^h   Ozaki, Yukio ⁱ   Matsuzaki, Masunori ^j  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g TENRI HOSPITAL   (Japan)

^h KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

ⁱ FUJITA HEALTH UNIVERSITY   (Japan)

^j YAMAGUCHI UNIVERSITY   (Japan)

more..

Author keywords

Acute coronary syndrome; Advanced glycation end products; Intravascular ultrasound; Plaque; Statins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ATORVASTATIN; PITAVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ACUTE CORONARY SYNDROME; AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; JAPAN; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84871899931     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-5     Document Type: Article

References (34)

1. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). J Am Coll Cardiol 2001, 37:1478-1492. 10.1016/S0735-1097(01)01175-5, 11300468.
2. von Birgelen C, Hartmann M, Mintz GS, van Houwelingen KG, Deppermann N, Schmermund A, Böse D, Eggebrecht H, Neumann T, Gössl M, Wieneke H, Erbel R. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 2004, 110:1579-1585. 10.1161/01.CIR.0000142048.94084.CA, 15364814.
3. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN, . REVERSAL Investigators Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080. 10.1001/jama.291.9.1071, 14996776, REVERSAL Investigators.
4. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM, . ASTEROID Investigators Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565. 10.1001/jama.295.13.jpc60002, 16533939, ASTEROID Investigators.
5. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004, 110:1061-1068. 10.1161/01.CIR.0000140261.58966.A4, 15326073.
6. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011, 365:2078-2087. 10.1056/NEJMoa1110874, 22085316.
7. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, . JAPAN-ACS Investigators Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009, 54:293-302. 10.1016/j.jacc.2009.04.033, 19608026, JAPAN-ACS Investigators.
8. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, . JAPAN-ACS Investigators Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome-serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial)-Circ J 2010, 74:1165-1174. 10.1253/circj.CJ-09-0766, 20467151, JAPAN-ACS Investigators.
9. Daida H, Takayama T, Hiro T, Yamagishi M, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M, . for the COSMOS Investigators High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: Results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Cardiovasc Diabetol 2012, 11:87. 10.1186/1475-2840-11-87, 3444370, 22831708, for the COSMOS Investigators.
10. Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, Schoenhagen P, Nissen SE. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008, 52:255-262. 10.1016/j.jacc.2008.03.051, 18634979.
11. Arai H, Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, . JAPAN-ACS Investigators More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome-sub-analysis of JAPAN-ACS study-J Atheroscler Thromb 2010, 17:1096-1107. 10.5551/jat.5660, 20675955, JAPAN-ACS Investigators.
12. An X, Yu D, Zhang R, Zhu J, Du R, Shi Y, Xiong X. Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study. Cardiovasc Diabetol 2012, 11:71. 10.1186/1475-2840-11-71, 3441242, 22709409.
13. Herder M, Arntzen KA, Johnsen SH, Mathiesen EB. The metabolic syndrome and progression of carotid atherosclerosis over 13 years. The Tromso study. Cardiovasc Diabetol 2012, 11:77. 10.1186/1475-2840-11-77, 3539868, 22738646.
14. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820. 10.1038/414813a, 11742414.
15. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011, 46:217-224. 10.1016/j.exger.2010.11.007, 21111800.
16. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002, 251:87-101. 10.1046/j.1365-2796.2002.00932.x, 11905595.
17. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des 2008, 14:979-986. 10.2174/138161208784139684, 18473849.
18. Basta G, Turco SD, Navarra T, Mazzarisi A, Cocci F, Coceani M, Bianchi M, Schlueter M, Marraccini P. Inverse Association between Circulating Levels of Soluble Receptor for Advanced Glycation End-Products and Coronary Plaque Burden. J Atheroscler Thromb 2012, 19:941-948. 10.5551/jat.10561, 22785051.
19. Peng WH, Lu L, Hu J, Yan XX, Zhang Q, Zhang RY, Chen QJ, Shen WF. Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients. Clin Biochem 2009, 42:1252-1259. 10.1016/j.clinbiochem.2009.04.017, 19439163.
20. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 2000, 6:114-125. 1949938, 10859028.
21. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 2010, 53:450-467. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
23. Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, Ochi H, Nonaka M, Nabeshima Y, Inoue M, Ishitobi T, Chayama K, Tazuma S. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22:1112-1119. 10.1111/j.1440-1746.2007.04943.x, 17559366.
24. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Yamada S, Takeuchi M, Fukami K, Ueda S, Adachi H, Matsui T, Okuda S, Yamagishi S. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism 2009, 58:1624-1628. 10.1016/j.metabol.2009.05.018, 19604520.
25. Tahara N, Yamagishi SI, Matsui T, Takeuchi M, Nitta Y, Kodama N, Mizoguchi M, Imaizumi T. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther 2012 Feb, 30:42-48.
26. Maeda S, Matsui T, Takeuchi M, Yoshida Y, Yamakawa R, Fukami K, Yamagishi S. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol Res 2011, 63:241-248. 10.1016/j.phrs.2010.11.008, 21115116.
27. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004, 95:233-238. 10.1161/01.RES.0000137876.28454.64, 15297385.
28. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003, 92:785-792. 10.1161/01.RES.0000065620.39919.20, 12623881.
29. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008, 57:2461-2469. 10.2337/db07-1808, 2518498, 18511846.
30. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, Lerner S, Bakr S, Li Q, Lu Y, Song F, Qu W, Gomez T, Zou YS, Yan SF, Schmidt AM, Ramasamy R. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 2006, 113:1226-1234. 10.1161/CIRCULATIONAHA.105.575993, 16505177.
31. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S, . Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications Research Group Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications Research Group Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003, 348:2294-2303. 2701300, 12788993, Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications Research Group Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications Research Group.
32. Yamagishi S, Matsui T, Nakamura K. Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers. Med Hypotheses 2008, 71:259-261. 10.1016/j.mehy.2008.03.020, 18448262.
33. Zhang Y, Luo Z, Ma L, Xu Q, Yang Q, Si L. Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation. Int J Mol Med 2010, 25:729-734.
34. Tekabe Y, Luma J, Einstein AJ, Sedlar M, Li Q, Schmidt AM, Johnson LL. A novel monoclonal antibody for RAGE-directed imaging identifies accelerated atherosclerosis in diabetes. J Nucl Med 2010, 51:92-97. 10.2967/jnumed.109.064659, 20008983.